Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SINO BIOPHARM (01177.HK) Plans to Launch 5 Innovative Products Annually Over Next 3 Yrs, Expects Landmark Out-Licensing Deal Soon
Recommend 34 Positive 64 Negative 19 |
||||
|
||||
|
SINO BIOPHARM (01177.HK) announced that the proportion of revenue from the Group’s innovative products has risen from 16% in 2018 to 42% in 2024, with expectations to exceed 50% in 2025, marking a successful milestone in the Group’s innovation transformation. Over the next three years, the Group plans to launch around five innovative products annually, aiming to further increase the proportion of revenue from innovative products to 60% by 2027. This growth momentum is largely driven by the Group’s dual-engine strategy of “in-house R&D + business development (BD)”. The Group has announced 12 innovative products with breakthrough data (including four Late-Breaking Abstracts (LBA)) at the American Society of Clinical Oncology (ASCO) Annual Meeting, achieving a major breakthrough. Since the beginning of this year, out-licensing has become one of the Group’s most critical strategic priorities, and an out-licensing deal is expected to be finalized soon. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
